Trastuzumab-conjugated liposomes for co-delivery of paclitaxel and anti-abcb1 siRNA in HER2-positive breast cancer: In vitro and in vivo evaluations

Document Type

Article

Publication Title

Journal of Drug Delivery Science and Technology

Abstract

Chemotherapeutic drugs often face challenges such as non-specific binding, undesired toxicity, and limited blood circulation, leading to reduced therapeutic efficacy. This study introduces HER2-specific targeted nanoparticles designed by synthesizing cationic liposomes. These liposomes encapsulate paclitaxel and ABCB1-siRNA in their core and feature a therapeutic monoclonal antibody, trastuzumab, on the surface. This design aims for precise targeting and synergistic treatment of HER2-positive breast cancer cells in both in vitro and in vivo models. The optimized trastuzumab-conjugated liposomes exhibited a particle size of 229 ± 4 nm and a zeta potential of 43.46 ± 0.61 mV. Their spherical morphology was confirmed using Scanning Electron Microscopy (SEM). These liposomes demonstrated enhanced drug retention in in vitro release studies. Furthermore, trastuzumab-conjugated liposomes displayed markedly higher cellular uptake than their non-trastuzumab-conjugated counterparts. Their anticancer efficacy in BT-474 cells significantly surpassed that of non-targeted liposomes and unencapsulated paclitaxel. In xenograft Nude mice models derived from the BT-474 cell line, trastuzumab-conjugated liposomes showed superior tumor distribution and preclinical effectiveness compared to both non-targeted liposomes and plain paclitaxel.

DOI

10.1016/j.jddst.2024.105614

Publication Date

5-1-2024

This document is currently not available here.

Share

COinS